Prima's CancerVac begins ovarian cancer trial
29 July, 2004 by Melissa TrudingerPrima Biomed (ASX: PRR) subsidiary CancerVac began a Phase IIa clinical trial today to evaluate its immunotherapy in patients with ovarian cancer.
Elastagen stretches commercial wings
29 July, 2004 by Graeme O'NeillNew Sydney University spinoff Elastagen is courting potential investors and commercial collaborators to develop organ-and-tissue-engineering applications for its super-stretchy protein, tropoelastin.
Peplin lead molecule active against leukaemia
28 July, 2004 by Renate KrellePeplin Biotech (ASX:PEP) has claimed its lead molecule PEP005 has shown highly selective activity against acute myelogenous leukaemia (AML) in pre-clinical studies.
Biotechs benefit from ARC grant round
28 July, 2004 by Renate KrelleSeveral Australian biotechs, including Novogen, Proteome Systems, Starpharma and Ventracor, were winners in the second round of Australian Research Council (ARC) linkage grants, announced earlier this month.
Polartechnics quadruples sales, but J&J drops TruScreen
28 July, 2004 by Renate KrelleSydney-based devices company Polartechnics (ASX:PLT) today announced its product-sales revenue had increased four-fold to AUD$2.14 million for the financial year ended June 30 2004.
Ventracor: device gets new application, third patient dies
27 July, 2004 by Renate KrelleSydney-based Ventracor (ASX:VCR) sent investors into a small spin today, announcing the broadening of its VentrAssist artificial heart Pilot Trial to include heart failure patients on transplant waiting lists.
Another patent for Psivida's portolio
27 July, 2004 by Graeme O'NeillPerth nano-biotech company Psivida (ASX:PSD) continues to add new patents to its bulging BioSilicon portfolio, and investors aren’t complaining.
British biotech Bone to list on ASX
27 July, 2004 by Melissa TrudingerWith the close of its placement expected on 3 August, British biotech company Bone is well on its way to a backdoor listing on the Australian Stock Exchange through former WA property management company Revenir (ASX: REV).
Cygenics secures second NIH contract
26 July, 2004 by Melissa TrudingerCyGenics (ASX: CYN) subsidiary Cytomatrix has secured a second year-long NIH contract worth US$272,000 for further development of its T cell technology.
Californian company licenses Ludwig research
26 July, 2004 by Graeme O'NeillCalifornian therapeutic antibody developer KalosBios Pharmaceuticals has joined the long list of international companies picking the fruits of Australian medical research.
Setback for rabbit control plan
23 July, 2004 by Graeme O'NeillPlans to use a genetically modified myxoma virus to depopulate Australia’s rabbit-ravaged landscapes of the continent’s worst mammalian pest have suffered a setback.
Aussies to spearhead eucalyptus genome project
22 July, 2004 by Susan WilliamsonScientists from around the world have agreed to collaborate on sequencing the complete eucalyptus genome, and formed the International Eucalyptus Genome Consortium at a meeting held in Hobart last week.
Proteome Systems boss critical of 'speculative' report
22 July, 2004 by Graeme O'NeillProteome Systems CEO Keith Williams has described as "highly speculative" a media report this morning which suggested his company might be valued only at AUD$100 million when it lists on the ASX this year, rather than the $300 million valuation it had hoped for.
Starpharma scoops up two ARC grants
21 July, 2004 by Graeme O'NeillStarpharma (ASX:SPL) has received two competitive linkage grants, worth a total of AUD$440,000 over the next three years, from the Australian Research Council to further develop pharmaceutical applications of its proprietary dendrimer macromolecules.
Anadis to raise $4.25m in private placement
21 July, 2004 by Renate KrelleMelbourne-based Anadis (ASX:ANX) is making the best of its lofty share price, announcing today that it will issue 10.9 million shares at AUD$0.30, raising $4.25 million.
